id:"swepub:oai:lup.lub.lu.se:5aeda821-e0e8-4cf5-86e4-c1ff6e873287"
Search: id:"swepub:oai:lup.lub.lu.se:5aeda821-e0e8-4cf5-86e4-c1ff6e873287" > Real-world cost-eff...
- 1 of 1
- Previous record
- Next record
- To hitlist
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib
- Ohm, Lotta (author)
- Lundqvist, Adam (author)
-
- Dickman, Paul (author)
- Karolinska Institutet
- show more...
- Carlsson, Katarina Steen (author)
- show less...
- (creator_code:org_t)
- 2014-10-21
- 2015
- English.
- In: Leukemia & Lymphoma. - : Informa UK Limited. - 1042-8194 .- 1029-2403. ; 56:5, s. 1385-1391
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical outcome and cost-effectiveness, using Swedish registry data based on patients with CML diagnosed 1973-2008. Outcome from three time periods (I: 1973-1979; II: 1991-1997; III: 2002-2008) associated with symptomatic treatment, interferon-alpha/stem cell transplant and implementation of imatinib, respectively, were compared and a lifetime cost-effectiveness model developed. Survival data from population registries, estimated resource use from clinical practice and quality of life estimates were employed. Substantial health gains were noted over time, paralleled by increased treatment costs. Median survival was 1.9, 4.0 and 13 years during the respective time periods. The incremental cost-effectiveness ratio (ICER) between periods III and II was (sic)52 700 per quality-adjusted life year (QALY) gained. An estimated 80% price reduction of imatinib, related to patent expiry, would reduce this ICER to (sic)22 700. Our data from four decades reveal dramatically improved survival in CML, paralleled by ICER levels generally accepted by health authorities.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Keyword
- Chronic myeloid leukemia
- survival
- population-based
- costs
- imatinib
- lifetime simulation
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
- Leukemia & Lymphoma (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Ohm, Lotta
- Lundqvist, Adam
- Dickman, Paul
- Höglund, Martin
- Persson, Ulf
- Stenke, Leif
- show more...
- Carlsson, Katari ...
- Bjorkholm, Magnu ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Health Sciences
- and Health Care Serv ...
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Hematology
- Articles in the publication
- Leukemia & Lymph ...
- By the university
- Lund University
- Uppsala University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
